Niagen Bioscience Taps Evotec to Advance Preclinical Development of Nb4168 Rare-Disease Candidate

Niagen Bioscience - Plans Ind Application to FDA for Nb4168

Niagen Bioscience Inc Expected to Post Earnings of 2 Cents a Share - Earnings Preview

Niagen Bioscience announces publication on muscle epigenetic age

Niagen Bioscience Reports Analysis Finds Niagen NR Cuts Muscle Epigenetic Age by About 2.5 Years in 5-month Trial

Niagen Bioscience (NAGE) Gets a Buy from Roth MKM

Niagen Bioscience CEO to Speak at Canaccord Genuity Growth Conference

Niagen Bioscience to Announce Second Quarter Financial Results on August 4

Niagen Bioscience Schedules Q2 Earnings Call After Market Close

Press Release: Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Niagen Bioscience Names Abhijit Kale Senior Director of Global External Research

Niagen Bioscience Appoints Abhijit Kale, Ph.d., as Senior Director of Global External Research

Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia

Niagen Rises After U.S., EU Rare Disease Designations for Drug Candidate

Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (rpd) Designation and European Medicines Agency Orphan Medicinal Product Designation (ompd) for Nb4168 for the Treatment of Ataxia Telangiectasia (a-t)

Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases

Niagen Bioscience launches pharmaceutical program for aging and genetic diseases

Niagen Bioscience initiated with a Buy at Freedom Broker

Niagen Bioscience Shareholders Back Board and Governance Measures